Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ORACLE-MS
  • Sponsors EMD Serono
  • Most Recent Events

    • 27 Feb 2021 Results (n=923) from CLARITY, CLARITY Extension, and ORACLE-MS trials, and the PREMIERE registry assessing effect of age at baseline in cladribine 3.5 mg/kg on levels of lymphocyte subsets, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021
    • 26 May 2020 Results of integrated safety analysis from CLARITY, CLARITY Extension, ORACLE-MS and PREMIERE studies presented at the 6th Congress of the European Academy of Neurology
    • 01 May 2020 Results (n=1564) of integrated pooled analysis from CLARITY, CLARITY Extension, and ORACLE MS trials, and the PREMIERE registry,providing updated safety data of cladribine tablets in the treatment of patients with multiple sclerosis presented at the 72nd Annual Meeting of the American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top